NASH: Nonalcoholic Steatohepatitis

Current Status
Not Enrolled
Get Started

Course: NASH: Nonalcoholic Steatohepatitis
Journal: Alimentary Pharmacology and Therapeutics
Credit: 2.0 AMA PRA Category 1 CreditsTM

Release Date: May 30, 2024

Educational Objectives

Upon completion of this activity, learners should be better able to:

  • review the global perspective on NAFLD and NASH
  • provide a narrative review on the performance and limitations of non-invasive tests, with a special emphasis on the impact of diabetes and obesity
  • explore the most up-to-date literature on testing used for monitoring disease progression and treatment response
  • review shared pathophysiologic features of common metabolic diseases and compare therapeutic strategies to reduce body weight and related complications

Handling Editors: Rohit Loomba, Vincent Wong

Authors: Pegah Golabi, Soroor Owrangi, Zobair M. Younossi, Shalini K. Bansal, Meena B. Bansal, Wah-Kheong Chan, Salvatore Petta, Mazen Noureddin, George Boon Bee Goh, Vincent Wai-Sun Wong, Nabil Noureddin, Nedret Copur-Dahi, Rohit Loomba, Anna Giannakogeorgou, Michael Roden

Activity Disclosures

Publication of this supplement is made possible by educational grant from Novo Nordisk.

No conflicts of interest or financial relationships relevant to this activity were reported.

Dr. Younossi is a consultant to BMS, Gilead, AbbVie, Abbott, Novo Nordisk, Madrigal, Merck, Siemens and Intercept. PG has no conflict of interest to disclose. W.K.C. served as a consultant or advisory board member for Roche, AbbVie, Boehringer Ingelheim and Novo Nordisk; and a speaker for Echosens, Viatris and Hisky Medical. G.G. served as a consultant or advisory board member for Boehringer Ingelheim, Gilead Sciences, Novo Nordisk and Roche Diagnostics; and a speaker for Abbott, Novo Nordisk and Echosens. V.W. served as a consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions and Visirna; and a speaker for Abbott, AbbVie, Gilead Sciences, Novo Nordisk and Unilab. He has received a research grant from Gilead Sciences, and is a co-founder of Illuminatio Medical Technology Limited. RL serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc. AG declares no competing interests. MR has received personal fees for consulting from Astra Zeneca, Eli Lilly, Novo Nordisk and Boehringer Ingelheim and is supported for investigator-initiated trials by Boehringer Ingelheim and Novo Nordisk.

This activity underwent peer review in line with standards of editorial integrity and publication ethics. Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.


John Wiley and Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. John Wiley and Sons, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within 2 hours. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to three years from initial publication. Additionally, a score of 70% or better is needed to pass the post test.

Link to content: Alimentary Pharmacology & Therapeutics | Pharmacology Journal | Wiley Online Library

Subscription access to Alimentary Pharmacology & Therapeutics is required for article content not under Open Access license.